Genmab A/S Sponsored ADR (NASDAQ:GMAB) Sees Significant Decrease in Short Interest

Genmab A/S Sponsored ADR (NASDAQ:GMAB) saw a significant decrease in short interest in January. As of January 30th, there was short interest totaling 8,413,829 shares, a decrease of 15.1% from the January 15th total of 9,908,231 shares. Based on an average trading volume of 2,151,118 shares, the days-to-cover ratio is presently 3.9 days. Approximately 1.3% of the company’s shares are short sold. Approximately 1.3% of the company’s shares are short sold. Based on an average trading volume of 2,151,118 shares, the days-to-cover ratio is presently 3.9 days.

Institutional Trading of Genmab A/S

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Personalized Indexing Management LLC increased its holdings in shares of Genmab A/S by 24.7% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 52,684 shares of the company’s stock worth $1,088,000 after acquiring an additional 10,426 shares during the last quarter. CWM LLC boosted its position in Genmab A/S by 50.5% during the second quarter. CWM LLC now owns 1,797 shares of the company’s stock worth $37,000 after purchasing an additional 603 shares during the period. Yousif Capital Management LLC increased its holdings in shares of Genmab A/S by 7.8% in the second quarter. Yousif Capital Management LLC now owns 10,943 shares of the company’s stock valued at $226,000 after purchasing an additional 790 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its position in shares of Genmab A/S by 200.8% in the second quarter. Caitong International Asset Management Co. Ltd now owns 5,809 shares of the company’s stock valued at $120,000 after purchasing an additional 3,878 shares during the period. Finally, Oppenheimer Asset Management Inc. lifted its stake in shares of Genmab A/S by 2.0% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 254,551 shares of the company’s stock worth $5,259,000 after buying an additional 5,083 shares during the last quarter. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Price Performance

NASDAQ GMAB traded down $0.03 on Tuesday, hitting $30.00. 3,036,551 shares of the stock were exchanged, compared to its average volume of 1,426,490. The business’s fifty day moving average is $32.31 and its 200 day moving average is $29.82. Genmab A/S has a 52 week low of $17.24 and a 52 week high of $35.43. The company has a market capitalization of $19.27 billion, a PE ratio of 14.51, a P/E/G ratio of 17.63 and a beta of 0.90.

Key Headlines Impacting Genmab A/S

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Company initiated a targeted share buy‑back to satisfy Restricted Stock Unit obligations (repurchase of up to 342,130 shares, max ~725 million DKK), which reduces float and signals capital allocation support for the stock. Genmab Announces Initiation of Share Buy-Back Program
• Positive Sentiment: Q4 results modestly beat EPS expectations: reported $0.47 EPS vs. $0.46 consensus, with revenue roughly in line at ~$1.06B and strong margins — a near-term fundamental positive. Q4 Slide Deck
• Positive Sentiment: Jefferies initiated coverage with a Buy and $41.50 target, representing meaningful upside vs. the current level — this can attract buyers and support sentiment. Benzinga
• Neutral Sentiment: Genmab published its 2025 Annual Report and filed Form 20‑F with the SEC — increases disclosure and transparency but is unlikely to move the stock materially on its own. Genmab Publishes 2025 Annual Report Genmab Files Annual Report (20-F)
• Neutral Sentiment: Morgan Stanley initiated coverage with an Equal Weight and $34 target — a mixed signal (coverage brings attention; Equal Weight is not a buy). Benzinga
• Neutral Sentiment: Investor materials and earnings‑call presentation posted (Seeking Alpha / slide deck) for deeper review of 2025 results and 2026 outlook. Useful for due diligence but not a headline mover. Earnings Presentation
• Neutral Sentiment: Short‑interest data reported appears anomalous (shows zero shares), so it offers no actionable signal to traders today.
• Negative Sentiment: Genmab updated FY‑2026 guidance but the published figures appear garbled/ inconsistent (revenue cited as “4.1–4.4 billionillion” vs. a cited consensus of “18.2 billionillion”). The unclear/likely erroneous guidance disclosure has likely increased investor uncertainty and could pressure the stock until clarified.

Analysts Set New Price Targets

A number of analysts recently issued reports on GMAB shares. Truist Financial reissued a “buy” rating and set a $48.00 target price (down from $49.00) on shares of Genmab A/S in a research note on Thursday, November 6th. Morgan Stanley assumed coverage on Genmab A/S in a report on Monday. They issued an “equal weight” rating and a $34.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $39.00 price objective on shares of Genmab A/S in a research report on Wednesday, January 28th. Zacks Research lowered Genmab A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 31st. Finally, Wall Street Zen downgraded Genmab A/S from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Six research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $41.10.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.